Quantum BioPharma Clarifies Name Confusion, Refutes RTO Rumors With Unbuzzd Wellness

Quantum BioPharma (QNTM) clarified that it has not changed its name despite some platforms incorrectly listing it as Unbuzzd Wellness Inc., and refuted rumors of a reverse takeover of Quantum by Unbuzzd. Unbuzzd Wellness, in which Quantum holds a significant stake, is preparing for a potential IPO, having appointed MNP LLP as auditor and engaged a New York investment bank for advisory services; Quantum remains Unbuzzd's largest shareholder and debt holder with royalty and anti-dilution rights. Quantum also announced it will settle $20,930 in vendor debt through Class B shares.

Analysis

Quantum BioPharma Ltd. (QNTM) has moved to dispel market confusion by unequivocally stating it has not changed its name to Unbuzzd Wellness Inc. and refuting rumors of a reverse takeover by Unbuzzd. This clarification is significant as Quantum holds a substantial financial interest in Unbuzzd Wellness Inc., a company specializing in alcohol metabolism aids, which is actively preparing for a potential Initial Public Offering (IPO). Unbuzzd's IPO preparations are underscored by the appointment of MNP LLP, a PCAOB-registered audit firm, and the prior engagement of a New York investment bank for advisory and capital raising. Quantum BioPharma's strategic position as Unbuzzd's largest shareholder and debt holder is reinforced by a lucrative agreement granting Quantum a 7% royalty on Unbuzzd's revenue until $250 million is paid (then 3%), 200 million post-split common shares, anti-dilution rights to potentially increase its stake to 25% within three years, and a $1.3 million secured loan extended to Unbuzzd at 10% interest. The credibility of Unbuzzd is further enhanced by its leadership, including former executives from Coca-Cola and Celsius Holdings. Separately, Quantum announced a minor settlement of USD $20,930 in vendor debt through the issuance of Class B Shares, a move expected to complete in early June 2025. QNTM's stock price remained unchanged at $15.20 on the Nasdaq Capital Market, indicating the market may be absorbing these clarifications and awaiting further developments regarding the Unbuzzd IPO. The overall moderately positive sentiment, with a specific QNTM sentiment score of 0.7, suggests these developments are viewed favorably.

Key Decisions for Investors

• Investors should closely monitor developments related to Unbuzzd Wellness Inc.'s potential IPO, as Quantum BioPharma's significant equity, debt holdings, and royalty agreement represent a primary potential value driver for QNTM.
• The clarification regarding Quantum's corporate identity and the dismissal of reverse takeover rumors remove a key uncertainty, which could positively influence investor perception and QNTM's valuation.
• Evaluate the potential long-term value accretion from Quantum's stake in Unbuzzd, considering Unbuzzd's experienced management and IPO trajectory, against the minimal dilutive impact from the share-based settlement of a small vendor debt.